Trending...
- Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
- Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
- Tacoma: Northbound I-705 Stadium Way Off-Ramp to Close at Noon Today for Emergency Repairs
UVify, a leader in the field of swarm and autonomous drones, is thrilled to announce its participation in the IEEE International Conference on Robotics and Automation (ICRA) 2023, which will take place in London from June 4 to June 9.
SEATTLE - Washingtoner -- UVify will be exhibiting its dynamic trio of drone models - the OMEGA, the IFO-S, and the IFO, throughout the duration of the conference. Each of these devices represents the cutting edge of swarm and autonomous technology, driving innovations in unmanned aerial operations.
Visitors to UVify's exhibit at ICRA 23 will have a unique opportunity to experience firsthand the sophisticated technology behind these advanced devices. Detailed demonstrations will showcase the remarkable capabilities of each drone, highlighting their powerful performance, superior agility, and innovative design.
More on Washingtoner
Adding to the excitement, members of UVify's development team will be on hand at the exhibit. This offers visitors a rare opportunity to engage in insightful discussions with the brilliant minds behind these groundbreaking drones.
"We are excited to participate in ICRA 23 and give visitors an intimate look at the advanced technology that powers our drones," says Robert Cheek, COO of UVify. "Our OMEGA, IFO-S, and IFO models reflect our commitment to pushing the boundaries of what's possible in the realm of autonomous and swarm drone technologies."
Don't miss out on the chance to witness these innovative drones in action at ICRA 23 from June 4 to June 9. For more information about UVify's participation at the event, visit www.uvify.com.
ABOUT UVIFY
UVify is an award-winning developer of autonomous and swarm robotics, specializing in drone technology. They are renowned for their innovation in creating high-performance drones designed to address the demands of various sectors, including research, entertainment, and business solutions.
Visitors to UVify's exhibit at ICRA 23 will have a unique opportunity to experience firsthand the sophisticated technology behind these advanced devices. Detailed demonstrations will showcase the remarkable capabilities of each drone, highlighting their powerful performance, superior agility, and innovative design.
More on Washingtoner
- Boston Industrial Solutions Introduces Personalized Printing Training
- Century Fasteners de Mexico Exhibiting at the 2026 Automotive & Aerospace Nearshoring Summit
- Spokane: Funding Available for Tourism and Culture Investment Grants
- Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
- FOCUS Names Mark Phillips Senior Vice President of Business Development
Adding to the excitement, members of UVify's development team will be on hand at the exhibit. This offers visitors a rare opportunity to engage in insightful discussions with the brilliant minds behind these groundbreaking drones.
"We are excited to participate in ICRA 23 and give visitors an intimate look at the advanced technology that powers our drones," says Robert Cheek, COO of UVify. "Our OMEGA, IFO-S, and IFO models reflect our commitment to pushing the boundaries of what's possible in the realm of autonomous and swarm drone technologies."
Don't miss out on the chance to witness these innovative drones in action at ICRA 23 from June 4 to June 9. For more information about UVify's participation at the event, visit www.uvify.com.
ABOUT UVIFY
UVify is an award-winning developer of autonomous and swarm robotics, specializing in drone technology. They are renowned for their innovation in creating high-performance drones designed to address the demands of various sectors, including research, entertainment, and business solutions.
Source: UVify
Filed Under: Technology
0 Comments
Latest on Washingtoner
- Spokane: Flags Lowered for Mayor Tim Verzal
- Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
- FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
- City of Tacoma Aligns Parking Rates and Facilities for Downtown Parking Network Effective October 13
- Bettingbladet releases H1 2026 report on the Swedish online gambling market
- Garage door installation or repair in Minnesota? Which makes more sense for your family?
- Tacoma: Application for 2027 Community Arts Projects Funding Now Available
- Haven Treatment Center Now In-Network Partnership with ComPsych, Expanding Access to Youth Health
- Tacoma: OMWBE Certification 201 Workshop on September 28
- Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
- European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
- VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
- Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
- Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
- Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
- Pebble Photo Booths Brings Modern Photo Experiences to Vancouver, Washington
- Spokane: Flags at Half-Staff in Remembrance of 9/11 Victims
- Haven Treatment Center Now In-Network with First Choice, Expanding Access to Youth Health
- Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
- FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)